Business News

Research and Markets: Injectable Generic Drugs: Prospects & Opportunities to 2013

2008-07-25 05:22:00

Research and Markets: Injectable Generic Drugs: Prospects & Opportunities to 2013

DUBLIN, Ireland–(EMWNews)–Research and Markets (

has announced the addition of the “Injectable Generic Drugs: Prospects &

Opportunities to 2013” report to their offering.

This report provides:

  • Individual analysis of 48 leading therapies

  • Product forecasts by value 2008/2013

  • Comprehensive patent information by product and patent expiry

    opportunities to 2015

  • The market context for injectable drugs

  • Evaluation of companies competing in the sector

  • Analysis of significant litigation

Key therapy sectors covered:

  • Cancer

  • CNS

  • Cardiovascular

  • Anti-Infectives

  • Diabetes

  • Growth Disorders

Some of the most promising generic drug opportunities due to come off

patent in the USA and Europe over the next few years are injectable.

This new report focuses on the market potential for sterile drugs

delivered by injection or infusion. These drugs are used to treat major

illnesses, such as cancer, central nervous system (CNS) disorders, acute

cardiovascular conditions and severe infections. More than one third of

the injectable generics approved in the US during the last five years

are used in cancer therapy. A further 23% are anti-infectives, 16% are

used in the CNS setting and 9% are used for cardiovascular therapy.

A relatively small number of injectable drugs have received significant

attention from generic companies, resulting in the approval of numerous

versions following patent expiry. Some of these are high profile cancer

drugs. For example, when Bristol-Myers Squibbs

Paraplatin (carboplatin) became generically available 11 companies

received FDA approval for generic versions.

Key Topics Covered:


Executive Summary


Leading Generic Markets


Major Therapeutic Areas

Leading Companies and Competition

EMEA Guidelines for Recombinant Granulocyte-Colony Stimulating Factor

Recombinant Human Growth Hormone

Appendix I: FDA ANDA Approvals

Appendix II: UK Injectable Generic Approvals


Companies Mentioned:

  • Amphastar Pharmaceuticals

  • Apotex

  • APP Pharmaceuticals

  • Baxter Healthcare

  • Bedford Laboratories

  • Hikma Pharmaceuticals

  • Hospira

  • Orchid Healthcare

  • Paddock Laboratories

  • PharmaForce

  • Sagent Pharmaceuticals

  • Sandoz

  • Sun Pharma

  • Teva Pharmaceutical Industries

  • Wockhardt

For more information visit

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood
Senior Manager

from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

free cash grants, free grant money, free money, cash grants, scholarships, business grants, foundation grants, government grants, debt grants, consolidation, college tuition, financial aid, medical grants, personal grants, medical bills, unsecured loans, no interest loans, financing, loans, capital, non profit organizations

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website now offers Organic Lead Generation & Traffic Solutions

Jordan Taylor

Jordan Taylor is Sr. Editor & writer from San Diego, CA. With over 20 years and 2650+ articles edited rest assured your Press Release will see traction.

Related Articles

Back to top button